Regulatory Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval Pharmaceutical TechnologyLantheus's radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) pathology.NeuroscienceRead full story pharminent August 17, 2026 (Last updated: August 18, 2026) Pharmaceutical Technology Lantheus’s radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) pathology. Neuroscience Read full story Post navigation Previous: BMS Wins First FDA Approval for CELMoD Class With Zenbexus in Multiple MyelomaNext: Sandoz targets industry patent void with $322m Henlius deal Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026